ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive: Therefore, we next used Annexin V and PI staining to assess cell death in Ba/F3 cells carrying wild-type or mutated BCR-ABL proteins and in CML cell lines treated with either a maximal dose of imatinib or increasing concentrations of ponatinib.